- Home
- GRX vs TLSI Comparison
GRX vs TLSI Comparison
Compare GRX & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRX
- TLSI
- Stock Information
- Founded
- GRX 2007
- TLSI 2010
- Country
- GRX United States
- TLSI United States
- Employees
- GRX N/A
- TLSI N/A
- Industry
- GRX Finance/Investors Services
- TLSI Medical Specialities
- Sector
- GRX Finance
- TLSI Health Care
- Exchange
- GRX Nasdaq
- TLSI Nasdaq
- Market Cap
- GRX 151.1M
- TLSI 124.9M
- IPO Year
- GRX N/A
- TLSI N/A
- Fundamental
- Price
- GRX $9.65
- TLSI $4.05
- Analyst Decision
- GRX
- TLSI Strong Buy
- Analyst Count
- GRX 0
- TLSI 6
- Target Price
- GRX N/A
- TLSI $11.75
- AVG Volume (30 Days)
- GRX 39.7K
- TLSI 54.4K
- Earning Date
- GRX 01-01-0001
- TLSI 11-14-2024
- Dividend Yield
- GRX 5.98%
- TLSI N/A
- EPS Growth
- GRX N/A
- TLSI N/A
- EPS
- GRX 0.26
- TLSI N/A
- Revenue
- GRX N/A
- TLSI $26,891,000.00
- Revenue This Year
- GRX N/A
- TLSI $60.97
- Revenue Next Year
- GRX N/A
- TLSI $53.69
- P/E Ratio
- GRX $38.50
- TLSI N/A
- Revenue Growth
- GRX N/A
- TLSI 67.90
- 52 Week Low
- GRX $7.73
- TLSI $3.50
- 52 Week High
- GRX $10.40
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- GRX 20.82
- TLSI 49.84
- Support Level
- GRX $10.06
- TLSI $3.60
- Resistance Level
- GRX $10.11
- TLSI $4.17
- Average True Range (ATR)
- GRX 0.14
- TLSI 0.37
- MACD
- GRX -0.09
- TLSI -0.03
- Stochastic Oscillator
- GRX 6.52
- TLSI 42.31
About GRX The Gabelli Healthcare & Wellness Trust of Beneficial Interest
Gabelli Healthcare & WellnessRx Trust operates as a diversified closed-end management investment company. The investment objective of the fund is the long-term growth of capital. The fund invests at least its assets in equity securities and income-producing securities of domestic and foreign companies in the healthcare and wellness industries. It invests in various sectors, of which Health Care Providers & Services, Food, Health Care Equipment and Supplies, and Pharmaceuticals account for the majority of the weightage.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.